AP NEWS

Mitogen Activated Protein Kinase 14 - Pipeline Review (H1 2018) Featuring AstraZeneca, Eli Lilly, GlaxoSmithKline, Array BioPharma, and more - ResearchAndMarkets.com

September 20, 2018

DUBLIN--(BUSINESS WIRE)--Sep 20, 2018--The “Mitogen Activated Protein Kinase 14 - Pipeline Review, H1 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Mitogen-activated protein kinase 14 also called p38-alpha is an enzyme belongs to p38 MAPK family.

ScopeThe report provides a snapshot of the global therapeutic landscape for Mitogen Activated Protein Kinase 14The report reviews Mitogen Activated Protein Kinase 14 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sourcesThe report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stagesThe report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activitiesThe report reviews key players involved in Mitogen Activated Protein Kinase 14 targeted therapeutics and enlists all their major and minor projectsThe report assesses Mitogen Activated Protein Kinase 14 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule typeThe report summarizes all the dormant and discontinued pipeline projectsThe report reviews latest news and deals related to Mitogen Activated Protein Kinase 14 targeted therapeutics

Companies Featured

Allinky BiopharmaArray BioPharma Inc.AstraZeneca plc Eli Lilly and Co.GlaxoSmithKline plc Ionis Pharmaceuticals Inc.Synovo GmbHTopiVert Ltd.Zocere Inc.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/wqptv4/mitogen_activated?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180920005381/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs,Enzymes

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/20/2018 07:18 AM/DISC: 09/20/2018 07:18 AM

http://www.businesswire.com/news/home/20180920005381/en

AP RADIO
Update hourly